A survey cited in the clinical literature found that 56% of respondents reported heightened anxiety as the most common withdrawal symptom, underscoring how central psychological distress can be in real-world withdrawal experiences as summarized in the withdrawal timeline review
An exciting development for those preferring pills over injections is the FDA's 2025 approval of the oral Wegovy option
Patients need clear and accurate information to navigate the complexities of accessing investigational drugs, advocating for their needs, and making informed decisions about their healthcare
The FDA-approved GLP-1 receptor agonists are exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and efpeglenatide (Eperzan)
These elements, combined with proper injection technique, form the comprehensive framework for successful Wegovy treatment